Stakeholder Input
Authors
- Pages
- 180
- Published in
- Canada
CADTH Reimbursement Review - Sacituzumab Govitecan (Trodelvy) - Sponsor: Gilead Sciences Canada, Inc.
24 Apr 2024
Accessing this content requires a membership
If your institution is a member, please log into Policy Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.
Add to list
Citation
Health, C., 2024. CADTH Reimbursement Review - Sacituzumab Govitecan (Trodelvy) - Sponsor: Gilead Sciences Canada, Inc., Canadian Agency for Drugs and Technologies in Health.
Canada.
Retrieved from https://coilink.org/20.500.12592/s7h4b52 on 07 Sep 2024. COI: 20.500.12592/s7h4b52.
Full-page Screenshot
